Phytoestrogens and Hepatocellular Carcinoma Chemoprevention
Abstract
Hepatocellular carcinoma (HCC) is the commonest primary malignant cancer of the liver and the third leading cause of cancer mortality worldwide. Statistically liver cancer is the fifth most common cancer in men and the 7th most common cancer in women. The major common risk factors for hepatocellular are hepatitis B (HBV) and hepatitis C viruses (HCV). Phytoestrogens are natural plant substances that are structurally or functionally similar to estradiol. The three main classes are isoflavones, coumestans, and lignans. Major source of phytoestrogen include, legume seeds (beans, peas), flax seed and especially soy products.Phytoestrogens have anticarcinogenic potential, but they have also significant estrogenic properties. Interest in phytoestrogens has been fueled by epidemiologic data that suggest a decreased risk of liver cancer in women from countries with high phytoestrogen consumption. In this review, the role of phytoestrogens and consumption of phytoestrogen-rich foods such as soy containing isoflavones, coumestans, and lignans for the prevention of hepatocellular carcinoma is reviewed.
Full Text:
PDFReferences
Raphael Raphe1, Willian J. Duca, Paulo C. Arroyo Jr et al. (2013) Hepatocellular carcinoma: Risk Factors, Diagnosis, Staging and Treatment in a Referral Centre. Journal of Cancer Therapy. 4 : 384-393
J. F. Perz, G. L. Armstrong, L. A. Farrington, W. J. Hutin and B. F. Bell, (2006) The Contributions of Hepatitis B Virus and Hepatitis C Infectious to Cirrhosis and Primary Liver Cancer Worldwide, Journal of Hepatology. 45 (4): 529-538.
F. B. Jemal, M. M. Center, J. Ferlay, E. Ward and D. Forman, (2011) Global Cancer Statistics, CA Cancer Journal of Clinical. 61( 2): 69-90
S. F. Altekruse, K. A. McGlynn and M. E. Reichman, (2009) Hepatocellular Carcinoma Incidence, Mortality, and Sur- vival Trends in the United States from 1975 to 2005,” Journal of Clinical Oncololy, 27 ( 9): 1485-1491.
World Health Organization, International Agency for Re- searches on Cancer, GLOBOCAN, (2008). http://globocan.iarc.fr
T. Y. M. Leong and A. S. Y. Leong, (2007) Epidemiology and Carcinogenesis of Hepatocellular Carcinoma,” HPB (Ox- ford), 7 (1) 5-15.
Michael C Kew. (2014) Hepatocellular carcinoma: epidemiology and risk factors. Journal of Hepatocellular Carcinoma;1 ;115–125
Mittal S, El-Serag HB. (2013) Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 47:55-66
Llovet JM, Burroughs A, Bruix J. (2003) Hepatocellular carcinoma. Lancet. 362:1907–1917.
Kew MC. (2014) The role of cirrhosis in the etiology of hepatocellular carcinoma. J Gastrointest Cancer. 45:12–21.
Wild CP, Pionneay F, Montesana R, et al. (1998) Aflatoxin detected in milk by immunoassay. Vir Hepatit Rev. 4;259–269.
Toth I, Yuan L, Rogers JT, Boyce H, Bridges KR. (1999) Hypoxia alters iron-regulatory protein-I binding capacity and modulates cellular iron homeostasis in human hepatoma and erythroleukemia cells. J Biol Chem. 274: 4467–4473.
Chuang SC, La Vecchia C, Boffetta P. (2009) Liver cancer: descriptive epide¬miology and risk factors other than HBV and HCV infection. Cancer Lett. 286:9–14.
Gandini S, Botteri E, Iodice S, et al. (2008) Tobacco smoking and cancer: a meta-analysis. Int J Cancer. 122: 155–164.
Shu-Chun Chuang a, Carlo La Vecchia b,c, Paolo Boffetta. (2009) Liver cancer: Descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Letters; 286: 9–14
J. Ferlay, F. Bray, P. Pisani, D.M. Parkin, Globocan (2002) Cancer Incidence, Mortality and Prevalence Worldwide, Version 2.0, Lyon, IARC CancerBase No. 5.
M.P. Curado, B. Edwards, H.R. Shin, H. Storm, J. Ferlay, M. Heanue, et al.(2007) Cancer Incidence in Five Continents, vol. IX (IARC Sci. Publ. No. 160), Lyon, IARC.
Surveillance, Epidemiology, and End Results (SEER) Program, SEER Stat Database: Incidence – SEER 17 Regs Limited-Use, Nov 2006 Sub (1973–2004 varying), released April 2007, Bethesda, MD, National Cancer Institute, www.seer.cancer.gov.
F. Berrino, R. De Angelis, M. Sant, S. Rosso, M. Bielska-Lasota, J.W. Coebergh, et al (2007) Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study, Lancet Oncol. 8, 773–783.
D.M. Parkin, F. Bray, J. Ferlay, P. Pisani (2005) Global cancer statistics, 2002, CA Cancer J. Clin. 55, 74–108.
R.K. RISHI. (2002) PHYTOESTROGENS IN HEALTH AND ILLNESS. Indian Journal of Pharmacology; 34: 311-320.
Rose DP, Boyar AP, Wynder EL(1986) International comparisons of mortality rates for cancer of the breast, ovary, prostate and colon, and per capita food consumption. Cancer; 58:2363-71.
Anderson JJB, Anthony M, Messina M, Garner SC.(1999) Effects of phyto-estrogens on tissues. Nutr Res Rev; 12:75-116.
Regina G Ziegler. (2004) Phytoestrogens and breast cancer. Am J Clin Nutr; 79:183–4.
Kurzer MS, Xu X.(1997) Dietary phytoestrogens. Annu Rev Nutr; 17: 353–81.
C. HERMAN, T. ADLERCREÃoeTZ, BARRY R. GOLDIN et al. (1995) Soybean Phytoestrogen Intake and Cancer Risk. J. Nutr. 125: 757S-770S.
MA Goetzl1, PJ VanVeldhuizen and JB Thrasher. (2007) Effects of soy phytoestrogens on the prostate, Prostate Cancer and Prostatic Diseases; 10 : 216–223
Usui T.(2006) Pharmaceutical prospects of phytoestrogens. Endocr J; 53: 7–20.
Murkies AL, Wilcox G, Davis SR. (1998) Phytoestrogens. J Clin Endocrinol Metab; 83:297-303.
Michelle Cotterchio , Beatrice A. Boucher , Michael Manno et al .(2006) Dietary Phytoestrogen Intake Is Associated with Reduced Colorectal Cancer Risk1. J Nutr; 136(12): 3046–3053.
De Kleijn MJ, van der Schouw YT, Wilson PW, Adlercreutz H, Mazur W, Grobbee DE, Jacques PF. (2001) Intake of dietary phytoestrogens is low in postmenopausal women in the United States: the Framingham Study. J Nutr; 131:1826–32.
Horn-Ross PL, Barnes S, Lee M, Coward L, Mandel JE, Koo J, John EM, Smith M. (2000) Assessing phytoestrogen exposure in epidemiologic studies: development of a database (United States). Cancer Causes Control; 11:289–98.
Milder IEJ, Feskens EJM, Arts ICW, de Mesquita HBB, Hollman PCH, Kromhout D. (2005) Intake of the plant lignans secoisolariciresinol, matairesinol, lariciresinol, and pinoresinol in Dutch men and women. J Nutr; 135:1202–7.
Bingham SA, Atkinson C, Liggins J, Bluck L, Coward A. (1998) Phyto-oestrogens: Where are we now? Br J Nutr; 9:393-406.
Reinli K, Block G. (1996) Phytoestrogen content of foods-a compendium of literature values. Nutr Cancer; 26: 123–148.
Wilson R. Cunha1, Mrcio Luis Andrade e Silva1, Rodrigo Cassio Sola Veneziani1. Lignans: Chemical and Biological Properties. Intech. 2009;5 (3) :234-257
Lilian U.Thompson, JianMin Chen, Tong Li, (2005) Dietary Flaxseed Alters Tumor BiologicalMarkers in Postmenopausal Breast Cancer. Clin Cancer Res;11(10) :3828-3851
Sherif M. Hassan. Soybean (2010) Nutrition and Health. Nutrition and Health. 3(6) :471-496
K. Griffiths, A.P.S. Hungin, F. De Meester et al (2013) Nutrition and Cancer. The Open Nutraceuticals Journal, 6 : 76-83.
Lucia Bacciottini, Alberto Falchetti, Barbara Pampaloni et al (2007) Phytoestrogens: food or drug?.Clinical Cases in Mineral and Bone Metabolism; 4(2): 123-130.
Michelle Cotterchio , Beatrice A. Boucher, Michael Manno et al. (2006) Dietary Phytoestrogen Intake Is Associated with Reduced Colorectal Cancer Risk1. J Nutr. 136(12): 3046–3053.
Tham DM, Gardner CD, Haskell WL. (1998) Potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J Clin Endocrinol Metab; 83:2223–35.
Thompson LU, Boucher BA, Liu Z, Cotterchio M, Kreiger N. (2006) Phytoestrogen content of foods consumed in Canada, including isoflavones, lignans and coumestan. Nutr Cancer; 54:184–201.
Setchell KDR.(1998) Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am J Clin Nutr; 68:1333S-46S.
K. Kushwaha1, C. A. O’Bryan , Dinesh Babu et al (2014) Human Health Benefits of Isoflavones From Soybeans. Agric. Food Anal. Bacteriol; 4: 122-142
Jane L Limer and Valerie Speirs (2004) Phyto-oestrogens and breast cancer chemoprevention. Breast Cancer Research; 6 ( 3) ;119-128
Franke AA, Custer LJ, Tanaka Y (1998) Isoflavones in human breast milk and other biological fluids. Am J Clin Nutr, Suppl: 1466S-1473S.
McMichael-Philips DF, Harding C, Morton M, Roberts SA, Howell A, Potten CS, Bundred NJ (1998) Effects of soy-protein supplementation on epithelial proliferation in the histologically normal human breast. Am J Clin Nutr, Suppl:1431S-1436S.
Hargreaves DF, Potten CS, Harding C, Shaw LE, Morton MS, Roberts SA, Howell A, Bundred NJ (1999) Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. J Clin Endocrinol Metab, 84: 4017-4024.
Lu L-J W, Anderson KE, Grady JJ, Kohen F, Nagamani M (2000) Decreased ovarian hormones during a soya diet: implications for breast cancer prevention. Cancer Res, 60:4112-4121.
Maskarinec G, Williams AE, Inouye JS, Stanczyk FZ, Franke AA (2002) A randomised isoflavone intervention among premenopausal women. Cancer Epidemiol Biomarkers Prev, 11:195-201.
Doostdar H, Burke MD, Mayer RT (2000) Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. Toxicology, 144:31-38.
Potter GA, Patterson LH, Wanogho E, Perry PJ, Butler PC, Ijaz T, Ruparelia KC, Lamb JH, Farmer PB, Stanley LA, Burke MD (2002) The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br J Cancer, 86:774-778.
Motoi TAMURA (2006) Effects of Intestinal Flora on the Metabolism and Absorption of Isoflavones. JARQ; 40 (1): 45-50.
Lampe, J. W. et al. (1998) Urinary equol excretion with a soy challenge: influence of habitual diet. Proc. Soc. Exp. Biol. Med. 217: 335–339.
Setchell, K. D. R. et al.(1984) Nonsteroidal estrogens of dietary origin: possible roles in hormone-dependent disease. Am. J. Clin. Nutr; 40: 569–578.
Gerald B. Sharp, Frederic Lagarde, Terumi Mizuno (2005) Relationship of hepatocellular carcinoma to soya food consumption. Int. J. Cancer; 115: 290–295.
Norie Kurahashi , Manami Inoue , Motoki Iwasaki (2009) Isoflavone consumption and subsequent risk of hepatocellular carcinoma in a population-based prospective cohort of Japanese men and women. Int. J. Cancer; 124, 1644–1649.
Hirayama T. (1989) A large-scale cohort study on risk factors for primary liver cancer, with special reference to the role of cigarette smoking. Cancer Chemother Pharmacol; 23 :114–17.
Kurozawa Y, Ogimoto I, Shibata A, Nose T, Yoshimura T, Suzuki H, Sakata R, Fujita Y, Ichikawa S, Iwai N, Fukuda K, Tamakoshi A. (2004) Dietary habits and risk of death due to hepatocellular carcinoma in a large scale cohort study in Japan. Univariate analysis of JACC study data. Kurume Med J; 51:141–9.
Sharp GB, Lagarde F, Mizuno T, Sauvaget C, Fukuhara T, Allen N, Suzuki G, Tokuoka S. (2005) Relationship of hepatocellular carcinoma to soya food consumption: a cohort-based, case-control study in Japan. Int J Cancer; 115:290–5.
Lei B, Roncaglia V, Vigano R, Cremonini C, De Maria N, Del Buono MG, Manenti F, Villa E. (2002) Phytoestrogens and liver disease. Mol Cell Endocrinol; 193:81–4.
Fukuda K, Shibata A, Hirohata I, Tanikawa K, Yamaguchi G, Ishii M.A (1993) hospital-based case-control study on hepatocellular carcinoma in Fukuoka and Saga Prefectures, northern Kyushu, Japan. Jpn J Cancer Res; 84:708–14.
Kuper H, Tzonou A, Lagiou P, Mucci LA, Trichopoulos D, Stuver SO, Trichopoulou A.(2000) Diet and hepatocellular carcinoma: a case-control study in Greece. Nutr Cancer; 38:6–12.
JOANNA WIETRZYK, GRZEGORZ GRYNKIEWICZ and ADAM OPOLSKI (2005) Phytoestrogens in Cancer Prevention and Therapy –Mechanisms of their Biological Activity. ANTICANCER RESEARCH; 25: 2357-2366
Peeters PH, Keinan-Boker L, van der Schouw YT and Grobbee DEL. (2003) Phytoestrogens and breast cancer risk. Review of the epidemiological evidence. Breast Cancer Res Treat; 77: 171-183.
Lee MM, Gomez SL, Chang JS, Wey M, Wang RT and Hsing AW (2003) Soy and isoflavone consumption in relation to prostate cancer risk in China. Cancer Epidemiol Biomarkers Prev; 12: 665-668.
Jane L Limer and Valerie Speirs (2004) Phyto-oestrogens and breast cancer chemoprevention. Breast Cancer Res, 6:119-127
Lu L-J W, Anderson KE, Grady JJ, Kohen F, Nagamani M (2000) Decreased ovarian hormones during a soya diet: implications for breast cancer prevention. Cancer Res, 60:4112-4121.
Peeters PHM, Keinen-Boker L, van der Schouw YT, Grobbee DE (2003) Phytoestrogens and breast cancer risk. Breast Cancer Res Treat, 77:171-183.
Maria Hedelin, Marie L, Therese M.-L. Andersson (2012) Dietary Phytoestrogens and the Risk of Ovarian Cancer in the Women's Lifestyle and Health Cohort Study. Cancer Epidemiol Biomarkers Prev; 20(2); 308–17
Chen X, Anderson JJ. (2001) Isoflavones inhibit proliferation of ovarian cancer cells in vitro via an estrogen receptor-dependent pathway. Nutr Cancer; 41:165–71.
Gercel-Taylor C, Feitelson AK, Taylor DD.(2004) Inhibitory effect of genistein and daidzein on ovarian cancer cell growth. Anticancer Res; 24: 795–800.
Gossner G, Choi M, Tan L, Fogoros S, Griffith KA, Kuenker M, et al. (2007) Genistein-induced apoptosis and autophagocytosis in ovarian cancer cells. Gynecol Oncol; 105:23–30.
Makela SI, Pylkkanen LH, Santti RS, Adlercreutz H.(1995) Dietary soybean may be antiestrogenic in male mice. J Nutr; 125:437–45.
Myung SK, Ju W, Choi HJ, Kim SC. (2009) Soy intake and risk of endocrinerelated gynaecological cancer: a meta-analysis. BJOG; 116: 1697–705.
Elisa V Bandera, Melony King, Urmila Chandran.(2011) Phytoestrogen consumption from foods and supplements and epithelial ovarian cancer risk: a population-based case control study. BMC Women’s Health; 7 (1): 11 – 40
Marion M. Lee, Scarlett Lin Gomez, Jeffrey S. Chang et al. (2003) Soy and Isoflavone Consumption in Relation to Prostate Cancer Risk in China1, Cancer Epidemiology, Biomarkers & Prevention. Vol. 12, 665–668.
Severson, R. K., Nomura, A. M., Grove, J. S., and Stemmermann, G. N. (1989) A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res; 49: 1857–1860
Jacobsen, B. K., Knutsen, S. F., and Fraser, G. E. (1998) Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study. Cancer Causes Control; 9: 553–557.
Kolonel, L. N., Hankin, J. H., Whittmore, A. S., Wu, A. H., Gallagher, R. P., Wilkens, L. R., John, E. M., Howe, G. R., Dreon, D. M., West, D. W., and Paffenbarger, R. S., Jr. (2000) Vegetables, fruits, legumes, and prostate cancer: a multiethnic case-control study. Cancer Epidemiol. Biomark. Prev., 9: 795–804.
Strom, S. S., Yamaura, Y., Duphorne, C. M., Spitz, M. R., Babaian, R. J., Pillow, P. C., and Hursting, S. D.(1999) Phytoestrogen intake and prostate cancer: a case-control study using a new database. Nutr. Cancer, 33: 20–25.
Peterson, G., and Barnes, S. Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation. Prostate, 22: 335–345, 1993.
Evans, B. A., Griffiths, K., and Morton, M. S. (1995) Inhibition of reductase in genital skin fibriblasts and prostate tissue by dietary lignans and isoflavonoids. J. Endocrinol., 147: 295–302.
Aronson, W. J., Tymchuk, C. N., Elashoff, R. M., McBride, W. H., Maclean, C., Wang, H., and Heber, D. (1999) Decreased growth of human prostate LNCap tumors in SCID mice fed a low-fat, soy protein diet with isoflavones. Nutr. Cancer, 35: 130–136.
Bylund, A., Zhang, J. X., Bergh, A., Damber, J. E., Widmark, A., Johansson, A., Adlercreutz, H., Aman, P., Shepherd, M. J., and Hallmans, G. (2000) Rye bran and soy protein delay growth and increase apoptosis in human LNCap prostate adenocarcinoma in nude mice. Prostate, 42: 304–314.
Zhou, J. R., Gugger, E. T., Tanaka, T., Guo, Y., Blackburn, G. L., and Clinton, S. K. (1999) Soybeans phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J. Nutr., 129: 1628– 1635.
Mentor-Marcel, R., Lamartiniere, C. A., Eltoum, I. E., Greenberg, N. M., and Elgavish, A. (2001) Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res., 61: 6777–6782.
Lin Yan and Edward L Spitznagel. (2009) Soy consumption and prostate cancer risk in men: a revisit of a meta-analysis. Am J Clin Nutr; 89:1155–63.
Pollard M, Wolter W. (2000) Prevention of spontaneous prostate-related cancer in Lobund-Wistar rats by a soy protein isolate/isoflavone diet. Prostate; 45:101–5.
Pollard M, Wolter W, Sun L. (2001) Diet and the duration of testosterone -dependent prostate cancer in Lobund-Wistar rats. Cancer Lett; 173:127–31.
Zhou JR, Yu L, Zhong Y, Blackburn GL. (2003) Soy phytochemicals and tea bioactive components synergistically inhibit androgen-sensitive human prostate tumors in mice. J Nutr; 133:516–21.
Hughes, I.; Woods, HF. (2003) Phytoestrogens and health. Food Standards Agency; London.
Messina M, Bennink M. (1998) Soyfoods, isoflavones and risk of colonic cancer: a review of the in vitro and in vivo data. Baillieres Clin Endocrinol Metab; 12:707–28.
Spector D, Anthony M, Alexander D, Arab L. (2003) Soy consumption and colorectal cancer. Nutr Cancer; 47:1–12.
Hoshiyama Y, Sekine T, Sasaba T. (1993) A case-control study of colorectal cancer and its relation to diet, cigarettes, and alcohol consumption in Saitama Prefecture, Japan. Tohoku J Exp Med; 171:153– 65.
Hu J, Liu Y, Yu YK, Zhao TZ, Liu SD, Wang QQ. (1991) Diet and cancer of the colon and rectum: a casecontrol study in China. Int J Epidemiol; 20:362–7.
Inoue M, Tajima K, Hirose K, Hamajima N, Takezaki T, Hirai T, Kato T, Ohno Y. (1995) Subsite-specific risk factors for colorectal cancer: a hospital-based case-control study in Japan. Cancer Causes Control; 6:14–22.
Nishi M, Yoshida K, Hirata K, Miyake H. (1997) Eating habits and colorectal cancer. Oncol Rep; 4:995–8.
Seow A, Quah SR, Nyam D, Straughan PT, Chua T, Aw TC. (2002) Food groups and the risk of colorectal carcinoma in an Asian population. Cancer; 95:2390–6.
Lechner D, Kallay E, Cross HS. (2005) Phytoestrogens and colorectal cancer prevention. Vitam Horm; 70:169–98.
Hirayama T. (1990) Contribution of a long-term prospective cohort study to the issue of nutrition and cancer with special reference to the role of alcohol drinking. Prog Clin Biol Res; 346:179–87.
Tajima K, Tominaga S. (1985) Dietary habits and gastrointestinal cancers: a comparative case-control study of stomach and large intestine cancers in Nagoya, Japan. Jpn J Cancer Res; 76:705–16.
International Classification of Diseases. Manual of the International Statistical Classification of disease, injuries, and causes of death. Proceedings of the 9th Revision Conference. Geneva: World Health Organization; 1977.
Greenland S. (1989) Modeling and variable selection in epidemiologic analysis. Am J Public Health; 79:340–9.
Webb A, McCullough ML. (2005) Dietary lignans: potential role in cancer prevention. Nutr Cancer; 51:117–31.
Horn-Ross PL, Lee M, John EM, Koo J. (2000) Sources of phytoestrogen exposure among non-Asian women in California, USA. Cancer Causes Control; 11:299–302.
Kolonel LN, Hankin JH, Whittemore AS, Wu AH, Gallagher RP, Wilkens LR, John EM, Howe GR, Dreon DM, et al. (2000) Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. Cancer Epidemiol Biomarkers Prev; 9:795–804.
Taylor CK, Levy RM, Elliott JC, Burnett BP (2009) The effect of genistein aglycone on cancer and cancer risk: a review of in vitro, preclinical, and clinical studies. Nutr Rev 67: 398-415.
Banerjee S, Li Y, Wang Z, Sarkar FH (2008) Multi-targeted therapy of cancer by genistein. Cancer Lett 269: 226-242.
De Souza PL, Russell PJ, Kearsley JH, Howes LG (2010) Clinical pharmacology of isoflavones and its relevance for potential prevention of prostate cancer. Nutr Rev 68: 542-555.
Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, et al. (1998) Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139: 4252-4263.
Basak S, Pookot D, Noonan EJ, Dahiya R. (2008) Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function. Mol Cancer Ther; 7: 3195-3202.
Pihlajamaa P, Zhang F, Saarinen L, Mikkonen L, Hautaniemi S, et al. (2011) The phytoestrogen genistein is a tissue-specific androgen receptor modulator. Endocrinology; 152: 4395-4405.
Davis JN, Kucuk O, Sarkar FH.(2002) Expression of prostate-specific antigen is transcriptionally regulated by genistein in prostate cancer cells. Mol Carcinog; 34: 91-101.
Mäkelä S, Poutanen M, Kostian ML, Lehtimäki N, Strauss L, et al. (2008) Inhibition of 17 beta-hydroxysteroid oxidoreductase by flavonoids in breast and prostate cancer cells. Cancer Epidemiol Biomarkers Prev; 12: 665-668.
Ebmeier CC, Anderson RJ. (2004) Human thyroid phenol sulfotransferase enzymes 1A1 and 1A3: activities in normal and diseased thyroid glands, and inhibition by thyroid hormones and phytoestrogens. J Clin Endocrinol Metab; 89: 5597-5605.
Adlercreutz H, Bannwart C, Wähälä K, Mäkelä T, Brunow G, et al. (1993) Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens. J Steroid Biochem Mol Biol; 44: 147-153.
Chen Y, Huang C, Zhou T, Chen G. (2008) Genstein induction of human sulfotransferases in Hep G2 and Cac0-2 cells. Basic Clin Pharmacol Toxicol; 103: 553-559.
Harris RM, Wood DM, Bottomley L, Blagg S, Owen K, et al. (2004) Phytoestrogens are potent inhibitors of estrogen sulfation: implications for breast cancer risk and treatment. J Clin Endocrinol Metab; 89: 1779-1787.
Luu-The V, Bélanger A, Labrie F. (2008) Androgen biosynthetic pathways in the human prostate. Best Pract Res Clin Endocrinol Metab; 22: 207-221.
Basly JP, Lavier MC. (2005) Dietary phytoestrogens: potential selective estrogen enzyme modulators? Planta Med; 71: 287-294.
Nishiyama T, Ogura K, Nakano H, Kaku T, Takahashi E, et al. (2002) Sulfation of environmental estrogens by cytosolic human sulfotransferases. Drug Metab Pharmacokinet; 17: 221-228.
Fotsis T, Pepper MS, Montesano R, Atkas E, Breit S, et al. (1998) Phytoestrogens and inhibition of angiogenesis. Baillieres Clin Endocrinol Metab; 12: 649-666.
Swami S, Krishnan AV, Moreno J, Bhattacharyya RS, Gardner C, et al. (2009) Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients. Int J Cancer; 124: 2050-2059.
Lakshman M, Xu L, Ananthanarayanan V, Cooper J, Takimoto CH, et al. (2008) Dietary genistein inhibits metastasis of human prostate cancer in mice. Cancer Res; 68: 2024-2032.
Xu L, Ding Y, Catalona WJ, Yang XJ, Anderson WF, et al. (2009) MEK4 function, genistein treatment, and invasion of human prostate cancer cells. J Natl Cancer Inst; 101: 1141-1155.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright ©2022 Academic Journals Center
To make sure that you can receive messages from us, please add the 'academicjournalscenter.org' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.